VivoSeq
Gastroenterology

Irritable Bowel Syndrome

161

Pipeline Programs↗

37

Active Trials↗

57

Companies Involved↗

Irritable Bowel Syndrome is a highly competitive landscape with 161 programs across 57 companies. The most active players are Arena Pharmaceuticals, Avera Pharmaceuticals, COMPASS Pathways. 33 therapies are approved with 33 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

43/100

Mech. Concentration

9/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Arena Pharmaceuticals

1 program

Phase 1A

Avera Pharmaceuticals

1 program

Phase 1COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1I

Ironwood Pharmaceuticals, Inc.

2 programs

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

168 of 174 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme32%Peptide32%

Small molecule leads; the ring shows all 174 classified programs, each share of the total. Modality classified for 99% of 186 pipeline programs.

Analysis

Trial Status

246

clinical trials

Completed156 · 63%
Unknown status25 · 10%
Recruiting21 · 9%
Terminated18 · 7%
Not yet recruiting12 · 5%
Withdrawn8 · 3%
Other6 · 2%

Clinical Trials

Trial Activity

246 trials

Efficacy of Fecal Microbiota Transplantation (FMT) in Irritable Bowel Syndrome (IBS)
Recruiting·TThammasat University·N/A·NCT06201182·45 enrolled
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
Recruiting·AbbVie logoAbbVie·Phase 2·NCT03339128·95 enrolled
Fecal Microbiota Transplantation for Irritable Bowel Syndrome Associated Food Intolerance
Recruiting·HHelsinki University Central Hospital·N/A·NCT05361785·45 enrolled
Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
Recruiting·—·N/A·NCT06788444·552 enrolled
Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome
Recruiting·UUniversity Hospital, Rouen·Phase 2·NCT07039747·100 enrolled
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
Recruiting·TTanta University·Phase 3·NCT04217733·60 enrolled
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Recruiting·BBiocodex·Phase 3·NCT07168434·406 enrolled
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Recruiting·—·N/A·NCT06681012·330 enrolled
Single-center Exploratory Study of the Intestinal Microbiota in Patients Treated for Irritable Bowel Syndrome With Predominant Constipation and Methane Production
Recruiting·HHospices Civils de Lyon·N/A·NCT06801184·40 enrolled
Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome
Recruiting·UUniversity Medical Center Ho Chi Minh City (UMC)·N/A·NCT07000383·90 enrolled
Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT06960369·400 enrolled
Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel Syndrome
Recruiting·XXiyuan Hospital of China Academy of Chinese Medical Sciences·Phase 1·NCT06737666·60 enrolled
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
Recruiting·JJinling Hospital, China·Phase 1·NCT06612411·180 enrolled
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
Recruiting·—·Phase 2/3·NCT07114055·60 enrolled
Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Recruiting·GGuangzhou First People's Hospital·Phase 2/3·NCT03613545·120 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)